Maintenance treatment in multiple myeloma

Annals of Oncology

Volumn 19, Issue SUPPL. 4, 2008, Pages

  Harousseau, J L ^a  

^a HÔTEL DIEU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BORTEZOMIB; CORTICOSTEROID; DEXAMETHASONE; LENALIDOMIDE; PAMIDRONIC ACID; THALIDOMIDE; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; DRUG DERIVATIVE; PYRAZINE DERIVATIVE;

ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER REGRESSION; CANCER SURVIVAL; CHROMOSOME DELETION; CLINICAL TRIAL; DRUG RESPONSE; HUMAN; MAINTENANCE THERAPY; MULTIPLE MYELOMA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGNOSIS; DISEASE FREE SURVIVAL; DRUG COMBINATION; METHODOLOGY; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; REMISSION; REVIEW; STEM CELL TRANSPLANTATION; SURVIVAL;

ANTINEOPLASTIC AGENTS; BORONIC ACIDS; DISEASE-FREE SURVIVAL; DRUG THERAPY, COMBINATION; HUMANS; MULTIPLE MYELOMA; PYRAZINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REMISSION INDUCTION; STEM CELL TRANSPLANTATION; SURVIVAL ANALYSIS; THALIDOMIDE;

EID: 48149114717     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn197     Document Type: Article

References (16)

1. Alexanian R, Balzerzac S, Haut A et al. Remission maintenance therapy for multiple myeloma. Arch Intern Med 1975; 135: 147-152.
2. Belch A, Shelley W, Bergsagel D et al. A randomized trial of maintenance versus no maintenance melphalan and prednisone in responding multiple myeloma patients. Br J Cancer 1986; 57: 94-99.
3. Berenson JR, Crowley JJ, Grogan TM et al. Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients. Blood 2002; 99: 3163-3168.
4. Shustik C, Belch A, Robinson S et al. Dexamethasone (dex) maintenance versus observation (obs) in patients with previously untreated multiple myeloma: A National Cancer Institute of Canada Clinical Trials Group Study: MY.7 (abstract). J Clin Oncol 2004; 145: 6510a.
5. Interferon as therapy for multiple myeloma: An individual patient data overview of 24 randomized trials and 4012 patents. The Myeloma Trialists' Collaborative Group. Br J Haematol 2001; 113: 1020-1034.
6. Fritz E, Ludwig H. Interferon-alpha treatment in multiple myeloma: meta-analysis of 30 randomized trials among 3948 patients. Ann Oncol 2000; 11: 1427-1436.
7. Cunningham D, Powles R, Malpas JS et al. A randomized trial of maintenance therapy with intron A following high dose melphalan and ABMT in myeloma. Br J Haematol 1998; 102: 195-202.
8. Barlogie B, Kyle RA, Anderson KC et al. Standard chemotherapy compared with high-dose chemoradiatherapy for multiple myeloma: Final results of Phase III US intergroup trial S9321. J Clin Oncol 2006; 24: 929-936.
9. Barlogie B, Tricot G, Anaissie E et al. Thalidomide and hematopoietic stem cell transplantation for multiple myeloma. N Engl J Med 2006; 354: 1021-1030.
10. Attal M, Harousseau JL, Leyvraz S et al. Maintenance therapy with thalidomide improves survival in multiple myeloma patients. Blood 2006; 15: 3289-3294.
11. Abdelkefi A, Ladeb S, Torjman L et al. Single autologous stem cell transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma: results of a multicenter randomized clinical trial. Blood 2007; 111: 1805-1810.
12. Spencer A, Prince HM, Roberts A et al. Thalidomide improves survival when used following ASCT (abstract). Haematologica 2007; 92: 41-42.
13. Singhal S, Mehta J, Desikan R et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341: 1565-1571.
14. Jagannath S, Richardson PG, Sonneveld P et al. Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2.3 trials. Leukemia 2007; 21: 151-157.
15. Sagaster V, Ludwig H, Kaufmann H et al. Bortezomib is relapsed multiple myeloma: Response rates and duration are independent of a chromosome 13q deletion. Leukemia 2007; 21: 164-168.
16. Bahlis NJ, Mansoor B, Lategan JC et al, Lenalidomide overcomes poor prognosis conferred by deletion of chromosome 13 and t(4; 14): MM016 trial (abstract). Blood 2006; 108: 1016a.